Jump to content
Powered by

Immatics appoints Carsten Reinhardt as Chief Medical Officer

The biopharmaceutical company immatics biotechnologies GmbH announced the appointment of Dr Carsten Reinhardt as Chief Medical Officer (CMO) effective October 1, 2009. “I am very pleased to be joining immatics at this exciting stage of the company’s development” said Dr Reinhardt.

Dr Reinhardt’s background, qualifications and experience fit perfectly with the goals
and expectations of immatics as the company looks to the rapid and further successful development of it’s lead clinical projects in renal cell carcinoma and colorectal cancer.

Dr Reinhardt joins immatics from Micromet, Inc., where he has headed the clinical
development team for the past four years, initially as Senior Vice President, Clinical
Development, and as Chief Medical Officer since June 2007. In this role, he was
responsible for all corporate medical, clinical, and regulatory activities. During his
tenure he headed the development team and moved various compounds into the clinic and successfully completed two key phase II studies. Dr. Reinhardt was also
significantly involved in achieving Micromet’s public listing on NASDAQ through a
reverse merger in 2006 and in repeated major financing rounds.

Before joining Micromet in 2005, Dr Reinhardt worked as International Medical Leader for Herceptin® at Hoffmann-La Roche (Basel, Switzerland) and before that as Head of Clinical Development at Fresenius Biotech (Munich, Germany), where he successfully developed later stage niche indication strategies leading to the recent approval of Removab®.

Prior to joining industry, Dr Reinhardt held medical positions and worked at various
academic institutions (University of Tuebingen, Max Planck Institute, Munich) to
complete his curriculum in Neurology. Between 1991 and 1995, Dr Reinhardt
completed his Ph.D. thesis in Cellular Immunology at the Institute of Immunology in Munich, Germany, and received a Medical Degree in 1994 from the University of
Munich, Germany. He is a Visiting Professor for Pharmaceutical Medicine at the
University of Basel.

“We are delighted to have been able to attract a CMO of Carsten‘s caliber and
experience”, commented Paul Higham, CEO of immatics. “He has successfully moved immunotherapy products into late stage clinical development. This combined with Carsten’s experience of working within a successful biotech company and his in-depth knowledge of immunotherapy matched exactly the profile we were looking for, as we enter late stage clinical development.”

“I am very pleased to be joining immatics at this exciting stage of the company’s
development” said Dr Reinhardt. “The encouraging results seen so far with the projects in clinical development and the high potential discovery platform both offer much promise in reaching the goals of immunotherapy in cancer treatment. I am looking forward to working with the team at immatics to realize this huge potential through successful late-stage clinical development of the lead projects.”

About immatics

Immatics biotechnologies is an independent biopharmaceutical company dedicated to
the development of active immunotherapies against cancer. immatics' therapeutic vaccines are based on multiple tumor-associated peptides (TUMAPs) which specifically
stimulate the immune system against cancer cells. Its lead products – IMA901 for the
therapy of renal cell cancer and IMA910 for the treatment of colon cancer – are currently investigated in international phase II clinical studies. Since its foundation in
2000, immatics has raised more than €54 million (US$ 72million) in private equity in
two financing rounds. The company has a headcount of more than 65 people and is
based in Tuebingen and Munich, Germany.

More information:

Katrin Eckert, Assistant to the Management
immatics biotechnologies GmbH
Phone: +49-7071-5397-110
E-mail: media(at)immatics.com

Website address: https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-appoints-carsten-reinhardt-as-chief-medical-officer